Embryonic Stem Cell Derivatives for Cardiac Therapy: Advantages, Limitations, and Long-Term Prospects

摘要: The ultimate goal of cardiovascular regenerative medicine is to ­generate functional myocardial tissue that can engraft, survive, mature, and become well integrated with host myocardium leading restoration the ­electromechanical properties. Human embryonic stem cells (hESCs) (Science 282:1145–7, 1998) offer a number theoretical advantages achieve this objective because their availability expandability, diverse ­differentiation capacity, proven capabilities robustly differentiate into lineages yielding appropriate molecular, structural, Despite these potential advantages, there are still important limitations need be addressed before clinical cell therapy hESCs realized. These include ethical immunological issues, technical issues for efficient ­production delivery­ cardiomyocytes, safety measures ­prevent ­possible misbehavior transplanted cells. recent introduction groundbreaking­ induced pluripotent technology, allowing reprogramming somatic ­pluripotent lines resembling hESCs, has provided another boost field ­further highlighted use cardiomyocytes derived from in several basic translational research areas.